Ingenuity Systems, Millennium Science announce a multi-year deal for Ingenuity Pathway Analysis with QFAB

Ingenuity Systems, the leading provider of information solutions for life science researchers, and Millennium Science, Ingenuity Systems' exclusive distributor for Australia and New Zealand, today announced a multi-year deal for Ingenuity Pathway Analysis (IPA) with the Queensland Facility for Advanced Bioinformatics (QFAB). IPA will become a significant component of a unique Integrated Systems Biology platform that has been funded by the Australian Research Council in partnership with the Australian Stem Cell Centre and other institutions. IPA will be used for data analysis and interpretation as part of QFAB's initiative to enable the global efforts of biotechnology, research biology, drug discovery, and translational medicine.

As part of the bioinformatics platform, IPA will serve as the primary solution to model, analyze, and identify key insights from high-throughput biomolecular data and curated datasets relating to health, biotechnology, and environmental processes. IPA will also help explore biomolecular network models and facilitate experimental validation.

"QFAB felt that IPA's powerful capabilities made it the perfect solution to include in a unique, state-of-the-art systems biology platform, and we are excited that this integration will help bring better biological insights to our customers in the Australia and the Asia-Pacific regions," stated Jeremy Barker, Chief Executive Officer, Queensland Facility for Advanced Bioinformatics.

"Advances in technology make it possible to capture and integrate more sophisticated types of data, yet the challenge is still interpreting the results and making informed conclusions. IPA is the ideal tool to rapidly make sense of complex data, which is why we are excited that the QFAB will use IPA as part of its platform," added Sean Scott, Senior Vice President, Commercial Operations, Ingenuity Systems.

Bren Collinson, Managing Director of Millennium Science, concluded, "This deal highlights the importance of developing and maintaining a solid relationship between Millenium, our customers, and our suppliers, and we are looking forward to working together with QFAB and Ingenuity in the future."


Ingenuity Systems


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
New collaborative effort focuses on therapeutic research for CDKL5 Deficiency Disorder